crestor
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.94 | $58.08 (0%) | 🛒 Add to cart |
| 60 | $1.52 | $116.17 $91.13 (22%) | 🛒 Add to cart |
| 90 | $1.37 | $174.25 $123.18 (29%) | 🛒 Add to cart |
| 120 | $1.30 | $232.34 $156.23 (33%) | 🛒 Add to cart |
| 180 | $1.22 | $348.50 $219.32 (37%) | 🛒 Add to cart |
| 270 | $1.18
Best per pill | $522.76 $318.46 (39%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.97 | $89.13 (0%) | 🛒 Add to cart |
| 60 | $2.20 | $178.26 $132.19 (26%) | 🛒 Add to cart |
| 90 | $1.96 | $267.39 $176.25 (34%) | 🛒 Add to cart |
| 120 | $1.83 | $356.52 $219.32 (38%) | 🛒 Add to cart |
| 180 | $1.70 | $534.77 $306.44 (43%) | 🛒 Add to cart |
| 270 | $1.61
Best per pill | $802.16 $435.63 (46%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.83 | $50.07 (0%) | 🛒 Add to cart |
| 90 | $0.75 | $75.11 $67.10 (11%) | 🛒 Add to cart |
| 120 | $0.71 | $100.14 $85.12 (15%) | 🛒 Add to cart |
| 180 | $0.67 | $150.22 $120.17 (20%) | 🛒 Add to cart |
| 270 | $0.63 | $225.33 $171.25 (24%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $300.43 $225.33 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Crestor, known generically as rosuvastatin calcium, is a synthetic lipid-lowering agent belonging to the statin class of medications. Marketed globally by AstraZeneca, this HMG-CoA reductase inhibitor represents one of the most potent prescription options for managing dyslipidemia. Unlike many dietary supplements that make vague health claims, Crestor operates through a well-defined biochemical pathway with extensive clinical validation spanning decades of research and real-world application.
Crestor: Potent LDL-C Reduction for Cardiovascular Risk Management - Evidence-Based Review
1. Introduction: What is Crestor? Its Role in Modern Medicine
Crestor contains the active pharmaceutical ingredient rosuvastatin calcium, a fully synthetic compound that inhibits HMG-CoA reductase—the rate-limiting enzyme in cholesterol biosynthesis. As a third-generation statin, Crestor demonstrates significantly greater potency in LDL-cholesterol reduction compared to earlier agents like atorvastatin and simvastatin. The medication’s primary role centers on atherosclerotic cardiovascular disease (ASCVD) risk reduction through comprehensive lipid parameter management, including LDL-C, non-HDL-C, and apoB lipoprotein.
What makes Crestor particularly significant in contemporary cardiology practice is its demonstrated efficacy across diverse patient populations—from primary prevention in intermediate-risk individuals to secondary prevention in established CAD patients. The JUPITER trial fundamentally changed how we approach statin therapy by demonstrating that even patients with “normal” LDL-C levels but elevated hs-CRP benefited substantially from rosuvastatin treatment.
2. Key Components and Bioavailability Crestor
The pharmaceutical composition of Crestor tablets includes rosuvastatin calcium in strengths of 5mg, 10mg, 20mg, and 40mg, alongside standard excipients like lactose monohydrate, tribasic calcium phosphate, crospovidone, and magnesium stearate. Unlike many dietary supplements with questionable absorption profiles, Crestor’s bioavailability is well-characterized at approximately 20%, with peak plasma concentrations occurring 3-5 hours post-administration.
The medication demonstrates minimal metabolism through cytochrome P450 pathways, with only about 10% undergoing CYP2C9 metabolism. This distinctive pharmacokinetic profile translates to reduced drug interaction potential compared to statins like simvastatin and atorvastatin that heavily depend on CYP3A4 metabolism. Food intake doesn’t significantly affect absorption, though we typically recommend evening administration to align with the circadian rhythm of cholesterol synthesis.
3. Mechanism of Action Crestor: Scientific Substantiation
Crestor works through competitive inhibition of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate in the hepatic cholesterol synthesis pathway. By blocking this rate-limiting step, rosuvastatin depletes intracellular cholesterol stores, triggering increased expression of LDL receptors on hepatocyte surfaces.
The upregulated LDL receptor activity enhances clearance of circulating LDL particles from the bloodstream, producing the dramatic LDL-C reductions for which Crestor is renowned. Beyond this primary mechanism, the medication demonstrates pleiotropic effects including improved endothelial function, reduced vascular inflammation, decreased oxidative stress, and stabilization of atherosclerotic plaques. These additional benefits likely contribute to the cardiovascular risk reduction observed even in patients who achieve only modest LDL-C lowering.
The structural characteristics of rosuvastatin—particularly its hydrophilic nature and unique fluorine substitution—contribute to its enhanced hepatoselectivity and reduced penetration into peripheral tissues compared to lipophilic statins. This property may underlie the relatively favorable muscle safety profile observed in clinical practice, though myalgias certainly still occur.
4. Indications for Use: What is Crestor Effective For?
Crestor for Primary Hypercholesterolemia
As first-line therapy for heterozygous familial and non-familial hypercholesterolemia, Crestor typically reduces LDL-C by 45-63% depending on dose, with the 40mg dose reserved for severe cases requiring >50% reduction. The response is generally dose-dependent, with each doubling producing approximately 6% additional LDL-C reduction—the “rule of 6” we often reference in clinical practice.
Crestor for Mixed Dyslipidemia
In patients with combined lipid abnormalities (elevated LDL-C, triglycerides, and low HDL-C), Crestor demonstrates robust efficacy across multiple parameters. Beyond LDL-C reduction of 45-63%, triglyceride reduction typically ranges from 20-35%, while HDL-C increases by 8-14%. This comprehensive lipid modulation makes it particularly valuable in metabolic syndrome and type 2 diabetes populations.
Crestor for Primary Prevention
The JUPITER trial established Crestor’s role in primary prevention for individuals with LDL-C <130 mg/dL but elevated high-sensitivity C-reactive protein (hs-CRP ≥2.0 mg/L). Rosuvastatin 20mg daily reduced the primary endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes) by 44% compared to placebo.
Crestor for Pediatric Patients
For children 8 years and older with heterozygous familial hypercholesterolemia, Crestor is approved at doses up to 20mg daily. The safety profile appears generally consistent with adult populations, though we maintain particular vigilance regarding growth and development parameters.
5. Instructions for Use: Dosage and Course of Administration
Initiation and titration of Crestor follows a standardized approach, though individualization based on patient characteristics and treatment goals is essential:
| Indication | Starting Dose | Maximum Dose | Administration Timing |
|---|---|---|---|
| Primary prevention | 10-20mg daily | 20mg daily | Evening with or without food |
| Hypercholesterolemia | 10-20mg daily | 40mg daily | Evening with or without food |
| Severe hypercholesterolemia | 20mg daily | 40mg daily | Evening with or without food |
| Pediatric HeFH | 5-10mg daily | 20mg daily | Evening with or without food |
Dose adjustments are necessary in specific populations:
- Asian patients: Consider 5mg starting dose due to increased systemic exposure
- Renal impairment (CrCl <30 mL/min): 5mg starting dose, not to exceed 10mg daily
- Concomitant cyclosporine: 5mg maximum daily dose
- Combination with gemfibrozil: Avoid if possible; if necessary, limit to 10mg daily
We typically assess lipid response 2-4 weeks after initiation or dose adjustment, then at 3-month intervals until goals are achieved, followed by semi-annual monitoring.
6. Contraindications and Drug Interactions Crestor
Absolute contraindications for Crestor include active liver disease, unexplained persistent elevations in serum transaminases, pregnancy, and breastfeeding. Relative contraindications encompass concomitant use with cyclosporine, significant renal impairment, and history of statin intolerance.
The drug interaction profile, while more favorable than earlier statins, still requires careful consideration:
| Interacting Drug Class | Effect | Clinical Management |
|---|---|---|
| Cyclosporine | ↑ Rosuvastatin exposure 7-11 fold | Maximum dose 5mg daily |
| Gemfibrozil | ↑ Rosuvastatin exposure 2 fold | Limit to 10mg daily |
| Antacids (Al/Mg containing) | ↓ Rosuvastatin absorption | Separate administration by 2 hours |
| Warfarin | Potential ↑ INR | Monitor INR closely after initiation |
| Protease inhibitors | Variable effects | Consider alternative statin |
The most concerning adverse effects include myopathy/rhabdomyolysis (0.1-0.5% incidence), hepatotoxicity (1-3% transaminase elevations), and new-onset diabetes (9% increased risk in JUPITER). We routinely monitor CPK and liver enzymes, though the utility of routine monitoring has been debated in recent guidelines.
7. Clinical Studies and Evidence Base Crestor
The evidence supporting Crestor spans hundreds of clinical trials, but several landmark studies deserve particular emphasis:
The JUPITER trial (2008) randomized 17,802 apparently healthy men and women with LDL-C <130 mg/dL and hs-CRP ≥2.0 mg/L to rosuvastatin 20mg or placebo. The trial was stopped early after median follow-up of 1.9 years due to a 44% reduction in the primary composite endpoint. All-cause mortality was reduced by 20%, challenging conventional LDL-C-centric treatment thresholds.
The SATURN study (2011) used intravascular ultrasound to demonstrate that rosuvastatin 40mg produced regression of coronary atherosclerosis in patients with CAD, with percent atheroma volume decreasing by 1.22% compared to 0.99% with atorvastatin 80mg—not statistically different but demonstrating potent effects for both agents.
The HOPE-3 trial (2016) expanded our understanding of statin therapy in intermediate-risk populations without cardiovascular disease, showing that rosuvastatin 10mg daily reduced cardiovascular events by 24% regardless of baseline lipid levels.
Real-world evidence from registries and observational studies generally confirms the randomized trial findings, though adherence challenges in clinical practice often attenuate the treatment benefits observed under controlled conditions.
8. Comparing Crestor with Similar Products and Choosing a Quality Product
When comparing Crestor to other statins, several distinguishing characteristics emerge:
| Statin | Average LDL-C Reduction | CYP Metabolism | Drug Interaction Potential | Evidence Strength |
|---|---|---|---|---|
| Rosuvastatin (Crestor) | 45-63% | Minimal (CYP2C9) | Low-moderate | Extensive |
| Atorvastatin (Lipitor) | 39-60% | Moderate (CYP3A4) | Moderate-high | Extensive |
| Simvastatin (Zocor) | 35-47% | Extensive (CYP3A4) | High | Extensive |
| Pravastatin (Pravachol) | 22-42% | Minimal | Low | Moderate |
For patients requiring >50% LDL-C reduction, Crestor typically represents the most appropriate choice. The decision between brand-name Crestor and generic rosuvastatin involves consideration of cost versus the theoretical benefits of consistent manufacturing processes with the branded product—though in practice, we find most patients do equally well with either.
9. Frequently Asked Questions (FAQ) about Crestor
How long does it take for Crestor to lower cholesterol?
Most patients achieve approximately 50% of their ultimate LDL-C reduction within 1-2 weeks, with maximal effect occurring by 4 weeks. We typically check levels at 4-6 weeks after initiation.
Can Crestor be taken with other cholesterol medications?
Combination with ezetimibe produces additive LDL-C reduction and is well-tolerated. Concomitant use with fibrates, particularly gemfibrozil, increases myopathy risk and requires careful consideration.
What should I do if I miss a dose of Crestor?
Take the missed dose as soon as remembered, unless it’s almost time for the next dose. Never double dose to make up for a missed one.
Are there dietary restrictions while taking Crestor?
No specific restrictions, though continuing a heart-healthy diet enhances treatment effectiveness. Grapefruit juice has minimal interaction with Crestor compared to other statins.
Does Crestor cause memory loss?
The FDA has issued warnings about cognitive effects with statins, but large studies haven’t demonstrated consistent association. In practice, we rarely observe this effect.
10. Conclusion: Validity of Crestor Use in Clinical Practice
Crestor remains a cornerstone of contemporary lipid management, offering potent LDL-C reduction with a generally favorable safety profile. The extensive evidence base supporting its efficacy across diverse patient populations, coupled with its distinct pharmacokinetic advantages, positions it as a first-line option for many patients requiring significant atherogenic lipoprotein reduction. While statin therapy decisions must always incorporate individual patient characteristics, risk factors, and preferences, Crestor’s risk-benefit profile supports its ongoing prominent role in cardiovascular risk reduction strategies.
I remember when we first started using rosuvastatin back in 2003—our cardiology group was divided between the established atorvastatin advocates and those of us impressed by the early rosuvastatin data. Dr. Williamson, our senior partner, was adamant that we were just chasing marginal gains with this new expensive agent. But then Maria Rodriguez, 52-year-old with familial hypercholesterolemia and previous intolerance to three other statins, came to us with LDL still hovering at 190 despite maximal non-statin therapy.
We started her on 5mg, fully expecting the myalgias to return within weeks. Six months later, not only was she symptom-free, but her LDL had dropped to 85—the first time it had been under 100 since her diagnosis decades earlier. That case alone converted several skeptics in our practice.
The real surprise came with our Asian patients though. We’d been following the standard dosing until Mr. Chen, 68-year-old with mild renal impairment, developed significant myositis on just 10mg. His CPK shot up to 1800, and we had to hold therapy for nearly a month. That experience taught us to really respect the pharmacokinetic differences in that population—something the trials had hinted at but didn’t fully prepare us for.
Over the years, I’ve noticed something interesting that never made it into the major trials: the patients who achieve the greatest LDL reductions often report unexpected benefits beyond cardiovascular protection. Sarah Jenkins, 61-year-old diabetic on 20mg, mentioned her chronic tendonitis resolved completely after 4 months on therapy. Another patient reported improvement in his xanthelasmas. We’ve speculated about localized anti-inflammatory effects, but honestly, we still don’t have a good mechanistic explanation.
The adherence challenge remains very real though—probably our biggest practical hurdle. Maybe 30% of our patients stop within the first year despite our best efforts at education. The ones who stick with it though? We’ve followed some for over 15 years now with maintained LDL control and minimal progression of their carotid plaques. That longitudinal benefit is what keeps me prescribing it despite the newer agents now available.
Just last week, Maria came for her annual follow-up—now 70 years old, still on that same 5mg dose, LDL at 78, and no clinical cardiovascular events after 18 years on therapy. When she thanked me for “saving her life,” I had to correct her: “The medication did the heavy lifting, Maria. I just wrote the prescription.” But moments like that remind you why evidence-based medicine matters.